Immatics (NASDAQ:IMTX – Get Free Report) and Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Profitability
This table compares Immatics and Achilles Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immatics | -47.94% | -15.90% | -9.38% |
| Achilles Therapeutics | N/A | -54.45% | -47.68% |
Risk & Volatility
Immatics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immatics | 0 | 0 | 4 | 1 | 3.20 |
| Achilles Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Immatics presently has a consensus price target of $16.67, indicating a potential upside of 133.75%. Achilles Therapeutics has a consensus price target of $4.00, indicating a potential upside of 253.98%. Given Achilles Therapeutics’ higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Immatics.
Institutional and Insider Ownership
64.4% of Immatics shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Immatics and Achilles Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immatics | $115.50 million | 7.37 | -$104.98 million | ($0.66) | -10.80 |
| Achilles Therapeutics | N/A | N/A | -$69.67 million | ($1.65) | -0.68 |
Achilles Therapeutics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Immatics beats Achilles Therapeutics on 8 of the 14 factors compared between the two stocks.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
